Alzamend Neuro is trading 6.78% down at $1.55 after falling from its August 28, 2026 close of $1.66; no company-specific announcement explaining the August 31 decline was identified.
- An August 21 Form S-1 registering up to 98.39 million shares for selling stockholders may remain an overhang, but it does not establish today’s cause.
- Broader markets are also lower, though the S&P 500, Nasdaq Composite, and Dow declines remain below 0.5%; trading activity and volume data were unavailable.